Canaccord Genuity maintains a 'Buy' on Protalix BioTherapeutics (PLX); PLX-105 Moves Ahead, More Proof of Concept for Platform
Tweet Send to a Friend
Canaccord Genuity maintains a 'Buy' on Protalix BioTherapeutics (NYSE Amex: PLX), price target $10.
Canaccord analyst says, "More validation of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "More validation of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
